Core Viewpoint - Dongwu Securities initiates coverage on RiboBio (06938) with a "Buy" rating and a target price of HKD 128.3, highlighting its leadership in the domestic small RNA field and the potential of its core product targeting FXI to become a billion-dollar FIC drug [1] Group 1: Company Overview - RiboBio, established in 2007, focuses on siRNA drug development for chronic diseases and possesses globally competitive proprietary GalNac delivery technology [1] - The company has a strategic partnership with Boehringer Ingelheim, potentially earning up to €2.36 billion in milestone payments, enhancing its market ceiling [1] - RiboBio's RiboGalSTAR technology platform is complemented by RiboOncoSTAR and RiboPepSTAR, positioning the company at the forefront of global small RNA drug development [1] Group 2: Market Potential - The global small RNA drug market is projected to grow from USD 5.7 billion in 2024 to USD 54.9 billion by 2033, with a CAGR of 21%-29% from 2024 to 2034, indicating a rapid growth trajectory [2] - RiboBio aims to convert its technological barriers into commercial value as a leading player in the domestic small RNA sector [2] Group 3: Product Pipeline and Clinical Progress - The FXI siRNA product has the potential to tap into a market space worth billions, addressing the clinical pain points of existing anticoagulant drugs while demonstrating long-lasting effects and safety [3] - The company is advancing its FXI siRNA into Phase 2 clinical trials, with expectations to initiate Phase 2b trials within the year [3] - RiboBio's pipeline includes several promising candidates targeting various chronic diseases, with significant global patient populations and market opportunities [4] - The APOC3 siRNA has commenced Phase 2 clinical trials in the EU, ranking among the top two globally, while the PCSK9 siRNA has exclusive rights in Greater China [4] - The HBV siRNA is in Phase 2 global MRCT clinical trials, aiming for functional cure, and the company has multiple candidates for IgAN entering clinical stages [4]